Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korro Bio, Inc.FREQ · Entity 6388 | Chief Development Officer | January 26, 2023 | January 27, 2023 |
| OTONOMY, INC.OTIC · Entity 116495 | Chief Scientific Officer | November 18, 2016 | November 22, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korro Bio, Inc.
Report date January 26, 2023 · Filed January 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 91,000 |
Reported balance
After 2023-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-26 · Grant · Acquired 91,000 · Balance 91,000 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024.
OTONOMY, INC.
Report date November 18, 2016 · Filed November 22, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,458 |
Ending reported balance
After 2016-11-21 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2016-11-18 · Exercise / conversion · Acquired 3,543 · Balance 13,001 Row 2 · 2016-11-18 · Exercise / conversion · Acquired 5,626 · Balance 18,627 Row 3 · 2016-11-18 · Sale · Disposed 9,169 · Balance 9,458 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $17.95 to $18.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 4 · 2016-11-21 · Exercise / conversion · Acquired 1,456 · Balance 10,914 Row 5 · 2016-11-21 · Sale · Disposed 1,456 · Balance 9,458 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $17.95 to $18.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.33 · Expires 2024-06-30 | Direct | 31,891 |
Reported balance
After 2016-11-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-11-18 · Exercise / conversion · Disposed 3,543 · Balance 31,891 F3: One-fourth of the shares subject to the option vested on April 23, 2015 and one forty-eighth of the shares vest monthly thereafter. F4: In addition to the remaining options to purchase 44,694 shares of common stock as set forth in Table II, the Reporting Person also holds options to purchase up to an aggregate of 239,392 shares of common stock, which options vest according to their terms. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.17 · Expires 2020-11-19 | Direct | 14,259 |
Reported balance
After 2016-11-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-11-18 · Exercise / conversion · Disposed 5,626 · Balance 14,259 F5: One-fourth of the shares subject to the option vested on November 19, 2011 and one forty-eighth of the shares vest monthly thereafter. F4: In addition to the remaining options to purchase 44,694 shares of common stock as set forth in Table II, the Reporting Person also holds options to purchase up to an aggregate of 239,392 shares of common stock, which options vest according to their terms. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.17 · Expires 2020-11-19 | Direct | 12,803 |
Reported balance
After 2016-11-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2016-11-21 · Exercise / conversion · Disposed 1,456 · Balance 12,803 F5: One-fourth of the shares subject to the option vested on November 19, 2011 and one forty-eighth of the shares vest monthly thereafter. F4: In addition to the remaining options to purchase 44,694 shares of common stock as set forth in Table II, the Reporting Person also holds options to purchase up to an aggregate of 239,392 shares of common stock, which options vest according to their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $17.95 to $18.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: One-fourth of the shares subject to the option vested on April 23, 2015 and one forty-eighth of the shares vest monthly thereafter.
F4: In addition to the remaining options to purchase 44,694 shares of common stock as set forth in Table II, the Reporting Person also holds options to purchase up to an aggregate of 239,392 shares of common stock, which options vest according to their terms.
F5: One-fourth of the shares subject to the option vested on November 19, 2011 and one forty-eighth of the shares vest monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2023 Filed Jan 27, 2023 16:37 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 91,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002456 · form4.xml · derivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024. F2 · derivative.expiration_date: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 57,500 | Not disclosed Strike: $25.05 | Not disclosed |
DisclosureSEC source: 0001127602-22-021376 · form4.xml · derivative · entry 6 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,500 shares Expires 2030-02-11 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 57,500 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021376 · form4.xml · derivative · entry 5 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2030-02-11 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 75,000 | Not disclosed Strike: $35.85 | Not disclosed |
DisclosureSEC source: 0001127602-22-021376 · form4.xml · derivative · entry 4 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2031-01-14 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 75,000 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021376 · form4.xml · derivative · entry 3 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-01-14 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 178,937 | Not disclosed Strike: $14.00 | Not disclosed |
DisclosureSEC source: 0001127602-22-021376 · form4.xml · derivative · entry 2 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 178,937 shares Expires 2029-10-01 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 178,937 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021376 · form4.xml · derivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,937 Underlying: Common Stock · 178,937 shares Expires 2029-10-01 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 16:47 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,421 | $1.52 | $6,719.92 |
DisclosureSEC source: 0001127602-22-019045 · form4.xml · nonDerivative · entry 2 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,343 F3 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.49 to $1.56. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 16:47 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-019045 · form4.xml · derivative · entry 3 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 16:47 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-019045 · form4.xml · nonDerivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 4638 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2022. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 16:36 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,069 | $3.53 | $3,772.50 |
DisclosureSEC source: 0001127602-22-006321 · form4.xml · nonDerivative · entry 2 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,126 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.40 to $3.73. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 16:36 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 974 | $3.87 | $3,772.30 |
DisclosureSEC source: 0001127602-22-006321 · form4.xml · nonDerivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,195 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.80 to $3.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 16:12 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005750 · form4.xml · derivative · entry 3 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units will fully vest on July 4, 2023. F5 · derivative.expiration_date: The restricted stock units will fully vest on July 4, 2023. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 16:12 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 901 | $4.19 | $3,774.29 |
DisclosureSEC source: 0001127602-22-005750 · form4.xml · nonDerivative · entry 2 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,169 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.00 to $4.50. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 16:12 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 831 | $4.43 | $3,680.50 |
DisclosureSEC source: 0001127602-22-005750 · form4.xml · nonDerivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,070 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.29 to $4.54. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 17:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 844 | $4.33 | $3,655.36 |
DisclosureSEC source: 0001127602-22-005336 · form4.xml · nonDerivative · entry 2 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,901 F3 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.28 to $4.40. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 17:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005336 · form4.xml · derivative · entry 3 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. F5 · derivative.expiration_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 17:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005336 · form4.xml · nonDerivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 745 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2021. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 16:16 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014285 · form4.xml · derivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $35.85 | $0.00 |
DisclosureSEC source: 0001127602-21-001992 · form4.xml · derivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-01-14 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 16:18 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 57,500 | $0.00 Strike: $25.05 | $0.00 |
DisclosureSEC source: 0001127602-20-005628 · form4.xml · derivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2030-02-11 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 15:00 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 23,555 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-028542 · doc4.xml · derivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,555 Underlying: Common Stock · 23,555 shares Expires 2029-04-16 F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| October 02, 2019 Filed Oct 2, 2019 21:38 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 178,937 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024830 · doc4.xml · derivative · entry 3 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,937 Underlying: Common Stock · 178,937 shares Expires 2029-10-01 F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023. Read SEC document |
| April 17, 2019 Filed Oct 2, 2019 21:38 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 101,930 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-024830 · doc4.xml · derivative · entry 2 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,930 Underlying: Common Stock · 101,930 shares Expires 2029-04-16 F1 · security: This transaction is being reported pursuant to Rule 16a-2(a), and the securities covered by such transaction were previously included on the Reporting Person's Form 3. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2019, and will be fully vested and exercisable on January 1, 2023. Read SEC document |
| April 17, 2019 Filed Oct 2, 2019 21:38 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 23,555 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-024830 · doc4.xml · derivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,555 Underlying: Common Stock · 23,555 shares Expires 2029-04-16 F1 · security: This transaction is being reported pursuant to Rule 16a-2(a), and the securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 17:57 UTC | OTONOMY, INC. OTIC · Entity 116495 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,456 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-16-151770 · doc4.xml · derivative · entry 8 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,803 Underlying: Common Stock · 1,456 shares Expires 2020-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: One-fourth of the shares subject to the option vested on November 19, 2011 and one forty-eighth of the shares vest monthly thereafter. F4 · balance_after: In addition to the remaining options to purchase 44,694 shares of common stock as set forth in Table II, the Reporting Person also holds options to purchase up to an aggregate of 239,392 shares of common stock, which options vest according to their terms. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 17:57 UTC | OTONOMY, INC. OTIC · Entity 116495 | SaleCommon Stock | 1,456 | $18.07 | $26,302.64 |
DisclosureSEC source: 0001209191-16-151770 · doc4.xml · nonDerivative · entry 5 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,458 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $17.95 to $18.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 17:57 UTC | OTONOMY, INC. OTIC · Entity 116495 | Exercise / conversionCommon Stock | 1,456 | $3.17 | $4,615.52 |
DisclosureSEC source: 0001209191-16-151770 · doc4.xml · nonDerivative · entry 4 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 17:57 UTC | OTONOMY, INC. OTIC · Entity 116495 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,626 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-16-151770 · doc4.xml · derivative · entry 7 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,259 Underlying: Common Stock · 5,626 shares Expires 2020-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: One-fourth of the shares subject to the option vested on November 19, 2011 and one forty-eighth of the shares vest monthly thereafter. F4 · balance_after: In addition to the remaining options to purchase 44,694 shares of common stock as set forth in Table II, the Reporting Person also holds options to purchase up to an aggregate of 239,392 shares of common stock, which options vest according to their terms. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 17:57 UTC | OTONOMY, INC. OTIC · Entity 116495 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,543 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-16-151770 · doc4.xml · derivative · entry 6 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,891 Underlying: Common Stock · 3,543 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth of the shares subject to the option vested on April 23, 2015 and one forty-eighth of the shares vest monthly thereafter. F4 · balance_after: In addition to the remaining options to purchase 44,694 shares of common stock as set forth in Table II, the Reporting Person also holds options to purchase up to an aggregate of 239,392 shares of common stock, which options vest according to their terms. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 17:57 UTC | OTONOMY, INC. OTIC · Entity 116495 | SaleCommon Stock | 9,169 | $18.07 | $165,703.08 |
DisclosureSEC source: 0001209191-16-151770 · doc4.xml · nonDerivative · entry 3 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,458 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $17.95 to $18.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 17:57 UTC | OTONOMY, INC. OTIC · Entity 116495 | Exercise / conversionCommon Stock | 5,626 | $3.17 | $17,834.42 |
DisclosureSEC source: 0001209191-16-151770 · doc4.xml · nonDerivative · entry 2 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 17:57 UTC | OTONOMY, INC. OTIC · Entity 116495 | Exercise / conversionCommon Stock | 3,543 | $6.33 | $22,427.19 |
DisclosureSEC source: 0001209191-16-151770 · doc4.xml · nonDerivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 18:55 UTC | OTONOMY, INC. OTIC · Entity 116495 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,304 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-16-140652 · doc4.xml · derivative · entry 10 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,885 Underlying: Common Stock · 5,304 shares Expires 2020-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: One-fourth of the shares subject to the option vested on November 19, 2011 and one forty-eighth of the shares vest monthly thereafter. F4 · balance_after: In addition to the remaining options to purchase 55,319 shares of common stock as set forth in Table II, the Reporting Person also holds options to purchase up to an aggregate of 239,392 shares of common stock, which options vest according to their terms. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 18:55 UTC | OTONOMY, INC. OTIC · Entity 116495 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,946 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-16-140652 · doc4.xml · derivative · entry 9 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,434 Underlying: Common Stock · 15,946 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth of the shares subject to the option vested on April 23, 2015 and one forty-eighth of the shares vest monthly thereafter. F4 · balance_after: In addition to the remaining options to purchase 55,319 shares of common stock as set forth in Table II, the Reporting Person also holds options to purchase up to an aggregate of 239,392 shares of common stock, which options vest according to their terms. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 18:55 UTC | OTONOMY, INC. OTIC · Entity 116495 | SaleCommon Stock | 5,304 | $17.95 | $95,206.80 |
DisclosureSEC source: 0001209191-16-140652 · doc4.xml · nonDerivative · entry 8 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,458 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 18:55 UTC | OTONOMY, INC. OTIC · Entity 116495 | SaleCommon Stock | 3,813 | $17.95 | $68,443.35 |
DisclosureSEC source: 0001209191-16-140652 · doc4.xml · nonDerivative · entry 7 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,762 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 18:55 UTC | OTONOMY, INC. OTIC · Entity 116495 | SaleCommon Stock | 12,133 | $17.95 | $217,787.35 |
DisclosureSEC source: 0001209191-16-140652 · doc4.xml · nonDerivative · entry 6 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,575 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 18:55 UTC | OTONOMY, INC. OTIC · Entity 116495 | Exercise / conversionCommon Stock | 5,304 | $3.17 | $16,813.68 |
DisclosureSEC source: 0001209191-16-140652 · doc4.xml · nonDerivative · entry 5 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 18:55 UTC | OTONOMY, INC. OTIC · Entity 116495 | Exercise / conversionCommon Stock | 3,813 | $6.33 | $24,136.29 |
DisclosureSEC source: 0001209191-16-140652 · doc4.xml · nonDerivative · entry 4 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 18:55 UTC | OTONOMY, INC. OTIC · Entity 116495 | Exercise / conversionCommon Stock | 12,133 | $6.33 | $76,801.89 |
DisclosureSEC source: 0001209191-16-140652 · doc4.xml · nonDerivative · entry 3 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2016 Filed Sep 8, 2016 18:55 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantCommon Stock | 275 | $13.13 | $3,611.44 |
DisclosureSEC source: 0001209191-16-140652 · doc4.xml · nonDerivative · entry 2 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,458 F1 · balance_after: Acquired pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| December 01, 2015 Filed Sep 8, 2016 18:55 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantCommon Stock | 263 | $13.60 | $3,576.80 |
DisclosureSEC source: 0001209191-16-140652 · doc4.xml · nonDerivative · entry 1 LeBel Carl · CIK 0001439275 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,183 F1 · balance_after: Acquired pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.